Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227303 | 0.88 | CYP2D6 (0.49) | KDM4EALDH1A1KMT2AMEN1ACHE | |
| SCHEMBL7243729 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1ACHEACKR3 | |
| SCHEMBL5223734 | 0.85 | CHRM4 (0.51) | KMT2AMEN1ACHESMN1; SMN2ACKR3 | |
| SCHEMBL5226356 | 0.84 | ALPL (0.40) | KDM4EALDH1A1KMT2AACHECYP3A4 | |
| SCHEMBL5224150 | 0.82 | ACHE (0.46) | KDM4EALDH1A1KMT2AMEN1ACHE | |
| SCHEMBL7243422 | 0.82 | ACKR3 (0.49) | KDM4EKMT2AMEN1ACHECYP3A4 | |
| SCHEMBL5228580 | 0.82 | ACKR3 (0.44) | KDM4EALDH1A1KMT2AMEN1ACHE | |
| SCHEMBL7244579 | 0.81 | KMT2A (0.47) | KDM4EALDH1A1KMT2AACHECYP3A4 | |
| SCHEMBL5225392 | 0.81 | ALDH1A1 (0.50) | KDM4EALDH1A1KMT2AMEN1ACHE | |
| SCHEMBL7246833 | 0.81 | ACKR3 (0.48) | KMT2AMEN1ACHEACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | KDM4E 2237/4885ALDH1A1 835/4885KMT2A 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.